Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus
Human metapneumovirus (HMPV) is one of the main pathogens causing severe respiratory infections in children, as a common cause of immunodeficiency-related deaths in children and elderly individuals, the prevalence of HMPV has been showing an increasing trend during the last years. However, no vaccin...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2023.2293300 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850185444156768256 |
|---|---|
| author | Shiyang Ma Fei Zhu Yizhong Xu Haicheng Wen Mingjun Rao Peipei Zhang Wenzhong Peng Yanhui Cui Hang Yang Caixia Tan Jie Chen Pinhua Pan |
| author_facet | Shiyang Ma Fei Zhu Yizhong Xu Haicheng Wen Mingjun Rao Peipei Zhang Wenzhong Peng Yanhui Cui Hang Yang Caixia Tan Jie Chen Pinhua Pan |
| author_sort | Shiyang Ma |
| collection | DOAJ |
| description | Human metapneumovirus (HMPV) is one of the main pathogens causing severe respiratory infections in children, as a common cause of immunodeficiency-related deaths in children and elderly individuals, the prevalence of HMPV has been showing an increasing trend during the last years. However, no vaccines or effective treatment plans are available currently. In this present, based on candidate proteins highly associated with viral virulence and has promising protective potential, we screened for immunodominant cytotoxic T cells, helper T cells, and Linear B-cell epitopes from the most promising candidate Fusion protein, together with G, SH, M, and M2. All epitopes were predicted to have strong antigenicity by Vaxijen and pose no potential toxicity, allergenicity, or hormonology to human proteins by Toxinpred, Allerpred, and Blast analysis, meanwhile, high conservancy is demanded to cover different subtypes. adjuvants β-defensin II and Pam2Cys was attached with EAAAK linkers to improve vaccine’s efficiency. Then, calculation of physicochemical properties proved the protein vaccine as a product can stably exist in the human body. Besides, we assessed the docking between the vaccine and immune receptors to evaluate its ability to stimulate immune responses, and the dynamic simulation further confirmed that the vaccine can tightly bind with immune receptors, which approved that the construction has the potential to induce strong humoral and cellular immune response. Finally, the vaccine was constructed into a multi-epitope mRNA vaccine, the immune simulations suggest that this is a vaccine candidate for controlling HMPV infection. |
| format | Article |
| id | doaj-art-911dfc3ecf6c40b1904c3f0a82ff1fa3 |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-911dfc3ecf6c40b1904c3f0a82ff1fa32025-08-20T02:16:44ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2023.2293300Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virusShiyang Ma0Fei Zhu1Yizhong Xu2Haicheng Wen3Mingjun Rao4Peipei Zhang5Wenzhong Peng6Yanhui Cui7Hang Yang8Caixia Tan9Jie Chen10Pinhua Pan11Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, ChinaDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Infection Control Center of Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaHuman metapneumovirus (HMPV) is one of the main pathogens causing severe respiratory infections in children, as a common cause of immunodeficiency-related deaths in children and elderly individuals, the prevalence of HMPV has been showing an increasing trend during the last years. However, no vaccines or effective treatment plans are available currently. In this present, based on candidate proteins highly associated with viral virulence and has promising protective potential, we screened for immunodominant cytotoxic T cells, helper T cells, and Linear B-cell epitopes from the most promising candidate Fusion protein, together with G, SH, M, and M2. All epitopes were predicted to have strong antigenicity by Vaxijen and pose no potential toxicity, allergenicity, or hormonology to human proteins by Toxinpred, Allerpred, and Blast analysis, meanwhile, high conservancy is demanded to cover different subtypes. adjuvants β-defensin II and Pam2Cys was attached with EAAAK linkers to improve vaccine’s efficiency. Then, calculation of physicochemical properties proved the protein vaccine as a product can stably exist in the human body. Besides, we assessed the docking between the vaccine and immune receptors to evaluate its ability to stimulate immune responses, and the dynamic simulation further confirmed that the vaccine can tightly bind with immune receptors, which approved that the construction has the potential to induce strong humoral and cellular immune response. Finally, the vaccine was constructed into a multi-epitope mRNA vaccine, the immune simulations suggest that this is a vaccine candidate for controlling HMPV infection.https://www.tandfonline.com/doi/10.1080/21645515.2023.2293300HMPVfusion proteinepitope dockingmolecular dynamicsmulti-epitope vaccinemRNA vaccine |
| spellingShingle | Shiyang Ma Fei Zhu Yizhong Xu Haicheng Wen Mingjun Rao Peipei Zhang Wenzhong Peng Yanhui Cui Hang Yang Caixia Tan Jie Chen Pinhua Pan Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus Human Vaccines & Immunotherapeutics HMPV fusion protein epitope docking molecular dynamics multi-epitope vaccine mRNA vaccine |
| title | Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus |
| title_full | Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus |
| title_fullStr | Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus |
| title_full_unstemmed | Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus |
| title_short | Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus |
| title_sort | development of a novel multi epitope mrna vaccine candidate to combat hmpv virus |
| topic | HMPV fusion protein epitope docking molecular dynamics multi-epitope vaccine mRNA vaccine |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2023.2293300 |
| work_keys_str_mv | AT shiyangma developmentofanovelmultiepitopemrnavaccinecandidatetocombathmpvvirus AT feizhu developmentofanovelmultiepitopemrnavaccinecandidatetocombathmpvvirus AT yizhongxu developmentofanovelmultiepitopemrnavaccinecandidatetocombathmpvvirus AT haichengwen developmentofanovelmultiepitopemrnavaccinecandidatetocombathmpvvirus AT mingjunrao developmentofanovelmultiepitopemrnavaccinecandidatetocombathmpvvirus AT peipeizhang developmentofanovelmultiepitopemrnavaccinecandidatetocombathmpvvirus AT wenzhongpeng developmentofanovelmultiepitopemrnavaccinecandidatetocombathmpvvirus AT yanhuicui developmentofanovelmultiepitopemrnavaccinecandidatetocombathmpvvirus AT hangyang developmentofanovelmultiepitopemrnavaccinecandidatetocombathmpvvirus AT caixiatan developmentofanovelmultiepitopemrnavaccinecandidatetocombathmpvvirus AT jiechen developmentofanovelmultiepitopemrnavaccinecandidatetocombathmpvvirus AT pinhuapan developmentofanovelmultiepitopemrnavaccinecandidatetocombathmpvvirus |